Oxcarbazepine

Strong UGT1A1 inducer that significantly decreases cabotegravir plasma concentrations. Coadministration is contraindicated.

Co-administration decreases doravirine plasma concentrations. At least a 4-week cessation period is recommended prior to initiation of PIFELTRO.

Co-administration decreases doravirine plasma concentrations and is contraindicated. At least a 4-week cessation period is recommended prior to initiation of DELSTRIGO.

Coadministration is contraindicated due to decreased rilpivirine plasma concentrations and loss of virologic response.

Coadministration is contraindicated. Induces CYP3A, resulting in decreased rilpivirine plasma concentrations and loss of virologic response.

P-gp inducer that decreases tenofovir alafenamide concentrations. Coadministration is not recommended.

Enzyme-inducing anti-epileptic drug that significantly decreases imatinib exposure.

Oxcarbazepine decreases lenacapavir concentration, risking loss of therapeutic effect and resistance. Concomitant use is not recommended.

Increases metabolism of contraceptive steroids, reducing contraceptive effectiveness and potentially resulting in unintended pregnancy or unscheduled bleeding.

May reduce contraceptive effectiveness and result in unintended pregnancy or breakthrough bleeding by increasing metabolism of contraceptive steroids.

May decrease contraceptive effectiveness and increase breakthrough bleeding through CYP3A4 induction.

May decrease plasma concentrations of COCs and potentially diminish effectiveness or increase breakthrough bleeding.

Concomitant use decreased perampanel plasma levels by 50-67%. Dose adjustment of FYCOMPA necessary; close monitoring required when introduced or withdrawn.

Carbamazepine decreases plasma levels of MHD (active metabolite) by 25-49%. Monitoring of MHD levels and oxcarbazepine dose adjustment may be necessary.

Decreases cyclosporine concentrations; appropriate dosage adjustment required.

Induces CYP3A4 and may decrease plasma concentrations of desogestrel and ethinyl estradiol, potentially diminishing contraceptive effectiveness and increasing breakthrough bleeding.

May decrease systemic concentrations of hormonal contraceptives and diminish effectiveness or increase breakthrough bleeding.

Induces CYP3A4 enzyme, may decrease effectiveness of COCs or increase breakthrough bleeding.

May decrease the effectiveness of hormonal contraceptives or increase breakthrough bleeding through CYP3A4 enzyme induction.

Enzyme inducer that may decrease effectiveness of COCs or increase breakthrough bleeding. Use back-up contraception.

Decreases TAF concentration. Consider alternative anticonvulsant.

CYP3A4 enzyme inducer that may decrease the effectiveness of the contraceptive or increase breakthrough bleeding.

May decrease plasma concentrations of etonogestrel and diminish contraceptive effectiveness or increase breakthrough bleeding.

CYP3A4 enzyme inducer that may decrease plasma concentrations of etonogestrel and ethinyl estradiol, potentially diminishing contraceptive effectiveness or increasing breakthrough bleeding.

Induces CYP3A4, may decrease plasma concentrations of CHCs and potentially diminish effectiveness or increase breakthrough bleeding.

May increase phenytoin serum levels; monitoring of phenytoin levels recommended.

CYP3A4 inducer may decrease serum hydrocortisone concentrations and increase risk of adrenal crisis; may require dose increase.

Oxcarbazepine induces CYP3A4 and may decrease plasma concentrations of COCs, potentially diminishing contraceptive effectiveness or increasing breakthrough bleeding.

Oxcarbazepine induces CYP3A4 enzymes, potentially decreasing contraceptive effectiveness and increasing breakthrough bleeding.

May decrease effectiveness of medroxyprogesterone acetate through enzyme induction. Counsel use of back-up or alternative contraception.

Enzyme inducer that may decrease plasma concentrations of CHCs and potentially diminish effectiveness or increase breakthrough bleeding.

CYP3A4 inducer that may decrease the effectiveness of COCs or increase breakthrough bleeding.

Enzyme inducer that may decrease plasma concentrations of norethindrone and ethinyl estradiol, potentially diminishing contraceptive effectiveness or increasing breakthrough bleeding.

May decrease plasma concentrations and efficacy of contraceptive; may increase breakthrough bleeding.

Oxcarbazepine may decrease the effectiveness of hormonal contraceptives, including oral and implant formulations.

Phenobarbital decreases plasma levels of MHD (active metabolite) by 25-49%. Monitoring of MHD levels and oxcarbazepine dose adjustment may be necessary.

Oxcarbazepine increases phenytoin levels at doses >1200 mg/day. Plasma level monitoring and dose reduction of phenytoin may be required.

May increase phenytoin serum levels; monitoring of phenytoin levels recommended.

Rifampin decreases plasma levels of MHD (active metabolite) by 25-49%. Monitoring of MHD levels and oxcarbazepine dose adjustment may be necessary.

Metabolic enzyme inducer that may decrease systemic concentrations of estrogen and/or progestin, potentially diminishing contraceptive effectiveness.

CYP3A4 inducer decreases plasma concentrations of ulipristal acetate and may decrease its effectiveness as emergency contraception.

Steady-state plasma concentrations of oxcarbazepine monohydroxy derivative were not affected by concomitant lacosamide at any dose in clinical studies.